ATH-434

ATH-434 is an orally bioavailable small molecule developed as a disease-modifying therapy for neurodegenerative disorders. It acts primarily by inhibiting the aggregation of pathological proteins such as alpha-synuclein and tau, and by restoring normal iron balance in the brain through moderate iron chelation. As an iron chaperone, it redistributes excess labile cellular iron without interfering with endogenous iron trafficking proteins like transferrin. Preclinical studies have shown that ATH-434 reduces alpha-synuclein pathology, oxidative stress markers, and preserves neuronal function in models of Parkinson’s disease and multiple system atrophy (MSA). In clinical trials for MSA, it has demonstrated significant slowing of disease progression and reduction of brain iron accumulation with a favorable safety profile[1][2][4][5][6].

Other names

ATH 434ATH434ATH-434PBT 434PBT434PBT-434